ENTX Stock Analysis: Buy, Sell, or Hold?
ENTX - Entera Bio Ltd. Ordinary Shares
$1.23
-0.10 (-7.52%)
▼
5d:
-20.65%
30d:
-30.51%
90d:
-57.73%
HOLD
MODERATE Confidence
Last Updated: February 3, 2026
Earnings: Mar 27, 2026
Get Alerted When ENTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ENTX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ENTX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ENTX is currently trading at $1.23, which is considered oversold relative to its 30-day fair value range of $1.43 to $1.77.
Technical Outlook: Technically, ENTX is in a downtrend. The price is currently testing key support at $1.23. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.5% recently.
Market Sentiment: ENTX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $10.00 (+713.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ENTX is in a downtrend. The price is currently testing key support at $1.23. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.5% recently.
Market Sentiment: ENTX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $10.00 (+713.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$1.43 -
$1.77
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.5%)
- BULLISH: Trading 713.0% below Wall St target ($10.00)
- CAUTION: 5-day price weakness (-20.6%) - monitor closely
Fair Price Analysis
30-Day Fair Range
$1.43 -
$1.77
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$1.23
Resistance Level
$1.67
Current Trend
Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
-1.81
Wall Street Target
$10.00
(+713.0%)
Revenue Growth (YoY)
-91.5%
Last updated: February 04, 2026 1:36 AM ET
Data refreshes hourly during market hours. Next update: 2:36 AM
Data refreshes hourly during market hours. Next update: 2:36 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ENTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$213 | 66 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$56 | 59 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$102 | 59 HOLD |
|
ARVN
Arvinas Inc |
BUY
21 analysts |
$13 | 58 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$47 | 54 HOLD |
